Mr
Harry
Gregson

Trainee Patent Attorney

Leeds Office

Chemistry

Telephone. +44(0) 113 233 0100
Email. [email protected]

Experience

In September 2018 Harry began work as a Trainee Patent Attorney in the Chemistry department of HGF Leeds. He has experience prosecuting patent applications relating to a variety of chemical and medical technologies in various jurisdictions. He has also assisted with drafting, opposition and appeals. Harry's experience has provided him with a good understating of the patent strategies adopted for some of our larger clients.

As part of his professional training Harry undertook a Postgraduate Certificate in Intellectual Property at Bournemouth University, obtaining a distinction.

For the third year of his Masters degree, Harry undertook a year in industry at a pharmaceutical manufacturing plant. His time here was spent in the lab developing and improving the manufacturing processes of certain APIs.

This experience provided Harry with an invaluable insight into the manufacturing process in the pharmaceutical industry, from early stage synthesis through to packaging.

Qualifications

Trainee


MCHEM

Chemistry with Medicinal Chemistry (with Industrial Training Year)

POSTGRADUATE DIPLOMA OR CERTIFICATE

Postgraduate Certificate Intellectual Property

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.